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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The
incidence of HCC varies considerably with the geographic area because of differences in the major causative
factors. Chronic hepatitis B and C, mostly in the cirrhotic stage, are responsible for the great majority of cases
of HCC worldwide. The geographic areas at the highest risk are South-East Asia and sub-Saharan Africa, here
hepatitis B is highly endemic and is the main cause of HCC. In areas with an intermediate rate of HCC such as
Southern Europe and Japan, hepatitis C is the predominant cause, whereas in low rate areas such as Northern
Europe and the USA, HCC is often related to other factors as alcoholic liver disease. There is a rising incidence
in HCC in developed countries during the last two decades, due to the increasing rate of hepatitis C infection and
improvement of the clinical management of cirrhosis.
Methods: This article reviews the literature on hepatitis and hepatocellular carcinoma. The Medline search was
carried out using these key words and articles were selected on epidemiology, risk factors, screening, and
prevention of hepatocellular carcinoma.
Results: Screening of patients with advanced chronic hepatitis B and C with hepatic ultrasound and determination
of serum alfa-fetoprotein may improve the detection of HCC, but further studies are needed whether screening
improves clinical outcome.
Hepatitis B and C viruses (HBV/HCV) can be implicated in the development of HCC in an indirect way, through
induction of chronic inflammation, or directly by means of viral proteins or, in the case of HBV, by creation of
mutations by integration into the genome of the hepatocyte.
Conclusion: The most effective tool to prevent HCC is avoidance of the risk factors such as viral infection. For
HBV, a very effective vaccine is available. Preliminary data from Taiwan indicate a protective effect of universal
vaccination on the development of HCC. Vaccination against HBV should therefore be a health priority. In
patients with chronic hepatitis B or C, interferon-alfa treatment in a noncirrhotic stage is protective for HCC
development in responders, probably by prevention of cirrhosis development. When cirrhosis is already present,
the protective effect is less clear. For cirrhosis due to hepatitis B, a protective effect was demonstrated in
Oriental, but not in European patients. For cirrhosis due to hepatitis C, interferon-alfa treatment showed to be
protective in some studies, especially in Japan with a high incidence of HCC in untreated patients. Virological, but
also merely biochemical response, seems to be associated with a lower risk of development of HCC. As most
studies are not randomized controlled trials, no definitive conclusions on the long-term effects of interferon-alfa
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in HBV or HCV cirrhosis can be established. Especially in hepatitis C, prospective studies should be performed
using the more potent reference treatments for cirrhotics, namely the combination of peginterferon and ribavirin.
Epidemiology of hepatocellular carcinoma
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignant tumors, representing more than 5% of all
cancers. The estimated annual number of cases exceeds
500,000 [1], with a mean annual incidence of around 3–
4% [2]. In terms of relative frequencies, HCC ranks as the
fifth most common cancer in the world, it is also the fifth
among men and eighth among women; it is the second
among cancers of the digestive tract after stomach cancer
[3].
The incidence of HCC varies considerably with the geo-
graphic area because of differences in the major causative
factors. The geographic areas at the highest risk are located
in Eastern Asia, with age-adjusted incidence rates (AAIR)
ranging from 27.6 to 36.6 per 100,000 in men; Middle
Africa (AAIR 20.8–31.1/100,000) and some Western Afri-
can countries (30–48/100,000). The geographic areas at
lowest risk are Northern Europe, Australia, New Zealand
and the Caucasian populations of North and Latin Amer-
ica (AAIR 1.5–3.0). In Southern Europe, AAIR is around
10 per 100,000 in men [3].
The most powerful risk factor for development of HCC is
the existence of liver cirrhosis, regardless of its etiology
[4]. Among cirrhotics, viral infection and high alcohol
intake are associated with the highest risk [5-8].
Of the primary hepatitis viruses, only hepatitis B and C
viruses cause HCC [9]. Hepatitis A and E viruses do not
produce long-term pathological sequelae. Although hepa-
titis D virus (HDV) always occurs as co-infection with
hepatitis B virus and leads to severe acute or chronic
hepatic disease, there is controversy whether it increases
the carcinogenic potential [10,11].
Risk factors for development of HCC
Hepatitis B
Hepatitis B virus (HBV) infection is a major public health
problem. It is estimated that two billion people have been
infected worldwide and 360 million suffer from chronic
HBV infection [12]. Over 520,000 die each year, 50,000
from acute hepatitis B, 470,000 from cirrhosis and liver
cancer. In South-East Asia hepatitis B is mostly acquired
perinatally from an infected mother. In sub-Saharan
Africa, it is mostly acquired in early childhood by hori-
zontal infection, whereas in Northwestern Europe, North
America and Australia infection is mainly through sexual
contact or needle sharing among injecting drug users,
with a peak incidence in the 15–25 age group [12]. Infec-
tion acquired perinatally and in early childhood is usually
asymptomatic, becoming chronic in 90 and 30% of cases,
respectively. In adults, infection resolves in >95% with
loss of serum HBsAg and the appearance of anti-HBs.
Chronic infection is characterized by the persistence of
HBsAg for more than 6 months. Acute hepatitis B usually
results in complete recovery with little if any risk of HCC.
In cases with persistent HBV infection, HBV is one of the
most important risk factors for HCC.
Chronic HBV infection presents as one of three potentially
successive phases: immune tolerant, immune active and low-
or non-replicative. In the immune tolerant phase, serum
HBsAg and HBeAg are detectable, serum HBV DNA levels
are high, serum aminotransferases are normal or mini-
mally elevated. In the immune active phase, serum HBV
DNA levels decrease and serum aminotransferase levels
increase. Flares of aminotransferases may be observed, in
some patients these flares are followed by HBeAg-anti-
HBe seroconversion. Following this conversion, in the
low- or non-replicative phase the HBV replication persists
but at a very low level suppressed by the host immune
response. HBV DNA in serum is undetectable by conven-
tional, non-PCR based techniques. This phase is also
called the 'inactive carrier state'. It may lead to resolution of
HBV infection where HBsAg becomes undetectable and
anti-HBs is detected, anti-HBc staying positive as sign of
contact with the virus. Recently it has been reported that
HBV DNA can persist in the serum and liver tissue even
after negativation of HBsAg [13]. Recent advances in
molecular technology have allowed the isolation of HBV
variants that either cannot produce HBeAg or produce it
less efficiently, based on precore stop codon mutation and
mutations in the core promoter region respectively. In
patients with HBV variants, progressive liver damage
occurs in parallel with relatively high levels of viremia. In
perinatally infected people, the immunotolerant phase
lasts till the age of 15–35 years, after which hepatitis flares
may occur, leading eventually to viral remission. In
patients infected during later childhood or adulthood,
there is no immunotolerant phase.
Most studies on the risk of developing HCC in chronic
HBV infection have been performed in the Far East. Here,
most patients acquired the HBV infection as newborn
infants [14]. It has been noted that the probability of
acquiring HCC increases with severity of liver disease. The
annual risk of HCC is 0.5% for asymptomatic HBsAg car-
riers and 0.8% for patients with chronic hepatitis B [15].World Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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Patients with HBV-cirrhosis have a 1000 times higher risk
of developing HCC compared to a HBsAg negative control
group [16]. The incidence of HCC in compensated cirrho-
sis due to HBV from Asia was 2.7%. In Japan, the mean
interval between the time of initial infection with HBV
and the occurrence of HCC is 50 years. As most people
here are infected at birth, HBV related liver cirrhosis usu-
ally develops in patients in their 40's and HCC in their
50's [17].
Few adequate studies have been performed in the West to
address the issue of the incidence of HCC in persons who
are positive for HBsAg. Most of the studies in Western
countries have included small numbers of HBsAg positive
patients and/or have not specifically analyzed the group
of HBsAg carriers. There is also lack of uniformity in the
timing of initiation of follow-up monitoring. In a cohort
of 350 Western European patients with compensated cir-
rhosis followed for a mean period of 6 years, the 5-year
cumulative incidence of HCC was 6% [18,19]. The inci-
dence was 2.2% in a series of 179 untreated Caucasian
patients [19,20]. In a retrospective analysis of cirrhotic
European patients with HBV infection, the 5-year inci-
dence of HCC was 9% irrespective of HBeAg or HBV DNA
status at the time of diagnosis of cirrhosis [21].
The hepatitis B replication status seems to play an impor-
tant role in determining the risk of development of HCC
[22-24]. A recent study found that whereas the relative risk
of HCC among men with HBsAg alone was 9.6 compared
to those without HBsAg, the risk increased to 60.2 when
they were positive for both HBsAg and HBeAg [23].
Another analysis showed that the level of HBV DNA is a
prognostic marker for HBV-related HCC and that HCC
patients with a less favorable course appear to either clear
the virus poorly or to have a greater level of virus produc-
tion [24]. It was recently demonstrated that positivity for
anti-HBc alone in absence of HBsAg and anti-HCV is not
rare in Japanese patients with HCC, which may indicate
that HBV virus might be involved in so-called non-B HCC
[25].
The entire nucleotide sequences of HBV genomes have
been classified into 8 genotypes (A-H), with predomi-
nance of genotypes A and D in Western countries, and B
and C in Southeast Asia and the Far East [26-29]. Several
studies from the Far East evaluated the association
between distinct genotypes and severity of liver disease.
Genotype C was shown to be associated with the develop-
ment of liver cirrhosis and HCC in Taiwan [30], China
[31] and Japan [32], whereas genotype B was shown rarely
to be associated with the development of HCC in China
and Japan. In contrast, in Taiwan genotype B is the pre-
dominant type in patients with HCC who are younger
than 35 years [30]. Another study from Taiwan showed
that patients with genotype C had a greater tumor recur-
rence rate after curative resection of HCC compared with
those with genotype B [33]. It was also shown that the
likelihood of presence of T1762/A1764 mutations in the
basal core promoter parallels the progression of liver dis-
ease, and that this mutation is found more frequent in
HBV genotype C than B patients [34]. PreS deletions were
shown to be more frequent in patients with HBV genotype
C, and associated with more advanced disease such as
liver cirrhosis and hepatocellular carcinoma [35].
Hepatitis C
Hepatitis C is also a major public health problem. There
are more than 170 million people infected worldwide
[36]. Approximately 80% of HCV infected patients
develop chronic hepatitis C. About 20% of these patients
will develop severe chronic hepatitis C and cirrhosis,
which becomes detectable in the second and third decade
after infection. The natural history of chronic hepatitis C
infection is characterized by a predominantly asympto-
matic course and a variable clinical outcome. For these
reasons it is difficult to define the rate of progression to
cirrhosis and HCC. The risk of cirrhosis in chronic hepati-
tis C is less than 10% in women infected at a young age
and >30% in men infected after the age of 40 over a 20
year period [37,38]. Five prospective studies from Europe
and the US have shown that during the first 10–15 years
after initial infection, liver cancer is a rare occurrence [39-
43]. In patients with hepatitis C, there is an increased risk
of HCC coinciding with the establishment of cirrhosis
with yearly incidence between 3–8% [6,7,44-47]. In
Japan, the mean interval between infection and develop-
ment of HCC is 30 years [48]. A study from the US shows
a long time lag (mean 28 years, range 8–42) between
transfusion-associated hepatitis and development of HCC
[49].
There is conflicting information on the relationship
between HCV genotype and progression to HCC in longi-
tudinal studies. It is suggested by some authors that geno-
type 1b (most prevalent in Europe and Japan) is
associated with a higher incidence of HCC than infection
with other genotypes [50,51]. In other studies, however,
this was not observed [52,53].
Coinfection of HBV and HCV
Both HBV and HCV are transmitted parenterally and coin-
fection is not uncommon in intravenous drug users and in
countries with a high prevalence of HBV [54]. Coinfection
of HBV and HCV seems to result in more severe liver dis-
ease than either infection alone [55]. The risk of develop-
ing HCC in subjects with both infections has been
investigated in a meta-analysis of 32 epidemiological
studies between 1993 and 1997 [56]. The odds ratio for
development of HCC in HBsAg positive, anti-HCV/HCVWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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RNA negative subjects was 20.4; in HBsAg negative, anti-
HCV/HCV RNA positive subjects 23.6; and subjects posi-
tive for both markers 135. These data suggest a more than
additive but less than multiplicative effect of HBV and
HCV coinfection on the relative risk for HCC. The viruses
may act through common as well as different pathways in
the carcinogenic process.
It has been reported that HBV DNA is still present after
seroconversion of HBsAg in patients with hepatitis B. Sev-
eral reports indicate that prior HBV infection, character-
ized by presence of anti-HBc, affects the development of
HCC in patients infected with HCV [57-59]. Given these
data, in patients with chronic HCV infection, serologic
markers of past HBV infection should be checked, not just
HBsAg. Other authors, however, were not able to docu-
ment any adverse event of occult HBV infection on the
clinicopathologic course of chronic HCV infection [60].
In case of coinfection with HBV (whether active or past),
a more aggressive surveillance to detect early HCC could
be suggested [61]. However, to date screening and surveil-
lance programs have not demonstrated a significant sur-
vival benefit.
In view of the role of HBV as cofactor in the development
of HCV related cirrhosis and HCC, vaccination of patients
with chronic hepatitis C against HBV has been advocated
with the presumption of avoiding additional liver injury
[62,63].
Coinfection of HBV and HDV
Verme et al [11] suggested that HBsAg positive patients
with HDV superinfection develop cirrhosis and HCC at an
earlier stage (mean age 48 year) than HBsAg carriers with-
out HDV infection (mean age 62 years).
Coinfection of HBV and HCV with HIV
Coinfection of HBV and HCV with HIV is common
because these diseases share the same routes of transmis-
sion. Recently a series of HCC in HIV-HCV coinfected
patients was published, indicating an unusually rapid
development of HCC in these patients [64]. This is not
surprising, as chronic hepatitis C is more aggressive in HIV
positive subjects, leading to cirrhosis and end-stage liver
disease in a shorter period of time [65].
Coinfection of HCV and S. mansoni
An Egyptian study showed that Schistosoma infection
increased the risk of HCC, only in the presence of HCV,
whereas isolated S. mansoni infection does not [66].
Role of alcohol consumption in HBV or HCV infection
Reports suggest that HBV and ethanol act synergistically to
promote HCC [67,68]. Habitual heavy drinking was
reported to be a significant risk factor for HCC in patients
with HCV-related liver cirrhosis by multiple logistic
regression analysis [57]. A recent study showed synergism
between alcohol drinking and HBV or HCV infection,
with approximately a twofold increase in the odds ratio
for each hepatitis virus infection for drinkers' > 60 g/d,
with a more than additive but less than multiplicative risk
[69]. Although two case-control studies did not show a
relationship of alcohol consumption with the occurrence
of HCC [70,71], another case-control study found a posi-
tive interaction between HBsAg positivity and HCV RNA
positivity and heavy alcohol intake in the development of
HCC [72]. Furthermore, Hassan et al. [73] showed syner-
gistic interaction (more than additive) between heavy
alcohol consumption ≥  80 ml/d and chronic HBV or HCV
infection (odds ratio 53.9) and insulin or non-insulin
dependent diabetes mellitus (odds ratio 9.9).
Incidence of HBV- and HCV-related HCC worldwide
Chronic hepatitis B and C infection are responsible for the
great majority of cases of HCC worldwide [9]. They also
account for the peculiar geographical distribution of the
tumor. The relative frequencies of HBV and/or HCV
related HCC in the world is illustrated in Table
1[17,72,74-93]. The worldwide incidence of HCC varies
and is predominantly related to the regional prevalence of
chronic viral hepatitis and its associated chronic liver dis-
ease and cirrhosis. Aflatoxin intake has a role in the gene-
sis of HCC only in patients who have pre-existing chronic
hepatitis B [84].
In the Far East and sub-Saharan Africa, where HBV is
highly endemic, HBV is the main cause of HCC.
In areas with an intermediate rate of liver tumors such as
Southern Europe, Egypt and Japan, HCV is the predomi-
nant cause of HCC. Here HCC is mostly discovered at an
older age in patients with longstanding cirrhosis due to
HCV.
In regions with a low incidence of HCC such as Northern
Europe and the United States, HCC related to HCV or
HBV infection are found in a minority of cases and the
tumor is often related to other factors such as alcoholic
liver disease. In these low endemic areas, HCC is usually
discovered at an older age in patients with longstanding
cirrhosis due to alcohol abuse [72]. In France, ethanol is
still the leading cause of cirrhosis and was responsible for
60% of all HCC causes during the last decade [8].
Time trends in the incidence of HCC
An important epidemiological fact is the rising incidence
of HCC in developed countries during the last two dec-
ades [79,89,95,99](Table 2).World Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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In Japan, the HCC-related mortality rate has sharply
increased since 1975 from 10/100,000 to almost 40/
100,000 in 2000 [99]. An analysis of the Shinshu Univer-
sity Hospital (Japan) showed a change in etiology of the
HCC [100]. Whereas in the 1971–1980 decade, hepatitis
B was the predominant cause of HCC, in the 1991–1995
period hepatitis C was largely predominant (Table 3).
However, the total numbers of yearly deaths because of
HCC in HBsAg carriers' stays constant, approximately
10% in the survey conducted in 1995. The rapid increase
Table 1: Relative frequencies of HBV and HCV related HCC in the world
Author [reference] Country Era Sample size HBsAg + (%) Anti-HCV + (%) HBsAg/anti HCV + (%) Other (%)
Chen, 1990 [74] Taiwan NR 66 35 (53.0) 15 (22.7) 7 (10.6) 9 (13.6)
Chuang, 1991 [75] Taiwan NR 128 87 (68.0) 13 (10.1) 12 (9.4) 16 (12.5)
Lee, 1992 [76] Taiwan NR 326 233 (71.5) 31 (9.5) 10 (3.1) 52 (15.9)
Jeng, 1991 [77] Taiwan NR 129 62 (48.1) 29 (22.5) 19 (14.7) 19 (14.7)
Leung, 1992 [78] Hong Kong 1986–90 424 341 (80.3) 16 (3.8) 15 (4.0) 52 (12.3)
Nishioka, 1990 [79] Japan NR 180 64 (35.6) 80 (44.4) 11 (6.1) 25 (13.9)
Saito, 1990 [80] Japan NR 253 49 (19.4) 136 (53.8) 2 (0.8) 66 (26.1)
Kiyosawa, 1990 [17] Japan 1958–89 83 19 (22.9) 51 (61.4) 10 (12.0) 3 (3.6)
Hassan, 2001 [81] Egypt 1995–96 33 5 (15.2) 25 (75.8) NR NR
Kew, 1990 [82] South Africa NR 380 137 (36.1) 63 (16.6) 47 (12.4) 127 (33.4)
Yu, 1990 [83] USA 1984–89 58 22 (37.9) 36 (62.1) NR NR
Di Bisceglie, 1991 [84] USA 1987–88 99 7 (7) 12 (12) 1 (1) 79 (79)
Hadziyannis, 1995 [85] Greece 1991–92 65 33 (50.8) 5 (7.6) 3 (4.5) 23 (38.3)
Colombo, 1989 [86] Italy 1975–88 132 19 (14.4) 64 (48.5) 22 (16.7) 27 (20.5)
Levrero, 1991 [87] Italy 1980–88 167 38 (22.8) 82 (49.1) 15 (9.0) 32 (19.2)
Simonetti, 1992 [88] Italy 1982–88 212 15 (7.1) 133 (62.7) 18 (8.5) 46 (21.7)
Donato, 1997 [72] Italy 1995–96 172 37 (21.5) 65 (37.8) 4 (2.3) 66 (38.4)
Stroffolini, 1998 [89] Italy 1996–97 1083 125 (11.5) 771 (71.2) 55 (5.1) 132 (12.2)
Bruix, 1989 [90] Spain NR 96 4 (4.2) 67 (69.8) 5 (5.2) 20 (20.8)
Nalpas, 1991 [91] France 1982–89 55 3 (5.5) 28 (50.9) 9 (16.3) 15 (27.3)
Van Roey, 2000 [92] Belgium 90s 154 37 (24.0) 62 (40.0) NR 55 (36.0)
Haydon, 1997 [93] UK 1985–94 80 13 (16.3) 22 (27.5) 2 (2.5) 43 (53.8)
NR: not reported; Bold: predominant cause
Table 2: Time trends on the incidence of HCC in the world
Author [reference] Country Number/100,000 era 1 Number/100,000 era 2
El Serag, 1999 [95] USA 1976–80: 1.4 1991–95: 2.4
El Serag, 2000 [96] USA 1993–95: 2.3 1996–98: 7.0
Benhamiche, 1998 [97] (men) France 1976–79: 7.5 1992–95: 10.2
Stroffolini, 1998 [89] Italy 1969: 4.8 1994: 10.9
Law, 2000 [98] (men) Australia 1983–85: 2.1 1995–96: 4.0
Nishioka, 1991 [79] Japan 1968–77: 9.5 1984–85: 16.0
Yoshizawa, 2002 [99] Japan 1980: ca 10 2000: ca 40
Table 3: Changing causes of HCC in Japan, 1971–95
Author [reference] Era Sample size HBsAg + (%) Anti-HCV + (%) HBsAg/anti HCV + (%) Other (%)
Kiyosawa, 1992 [100] 1971–80 112 60 (54%) 38 (34%) 5 (4%) 9 (8%)
1981–90 267 82 (31%) 159 (59%) 4 (2%) 22 (8%)
1991–95 162 21 (13%) 126 (78%) 5 (3%) 10 (6%)
Bold: predominant causeWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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of mortality due to HCC in Japan is mainly attributable
(ca 80%) to persistent infection with HCV [99]. The hep-
atitis C epidemic in Japan originated due to intravenous
drug use by the young generation after World War II dur-
ing the late 40s and early 50s. It spread in the general pop-
ulation due to remunerated blood donors. Abrogation of
paid blood donation in 1968, exclusion of blood units
contaminated with HBV in 1973 and HCV in 1989
decreased the risk of posttransfusion hepatitis from > 50%
in the 60s to almost zero at present. The incidence of HCV
in Japan is decreasing. As the interval between the time of
the initial infection with the hepatitis C virus and the
development of HCC is 30 years [79], the growing inci-
dence of HCC in Japan is expected to reach a plateau
around the year 2015, and then to decrease [99].
Also in Italy the mortality rate of HCC is rising [89] from
4.8/100,000 in 1969 to 10.9/100,000 in 1994, reflecting
the large cohort of subjects infected with HCV through
iatrogenic route during the 50s and 60s when glass
syringes were commonly used for medical treatment.
Likewise in Australia, France and the United States of
America (US) the HCC mortality is increasing, most prob-
ably because people infected with HCV have grown old
and reach the cancer-bearing age [95-98]. In the US, an
increase of about 80% in the incidence of HCC over the
past 20–30 years is described, it is estimated that approx-
imately 15,000 new cases occur each year. Also in France
the incidence of HCC is steadily and markedly increased,
the estimated number being about 4,000 per year [101].
Although the prevalence of HCV is declining in developed
countries because of the decline in incidence in the 90s,
the number of persons infected for ≥  20 years is expected
to increase substantially before peaking in 2015 [102].
Analysis of long-term serial HCV samples from the US and
Japan suggest that HCV was introduced into the US popu-
lation around 100 years ago and widely disseminated in
the 1960s. In contrast, HCV was introduced in Japan >
100 years ago and widely disseminated in the 1930s and
40s. The HCV genotype 1b population in Japan started to
decrease around 1995 whereas HCV genotype 1a in the
US is still growing exponentially. It is predicted that an
increased HCC prevalence will occur in the US over the
next two to three decades [103].
The reasons advocated for explaining the increased inci-
dence of HCC are the increased rate of HCV infection and
an improvement of the clinical management of cirrhotic
patients. Enhancing the survival of patients with advanced
cirrhosis leads to an increased incidence of HCC. In fact, a
decade ago, most of the deaths in cirrhotic patients were
due to digestive hemorrhage or bacterial infections, two
conditions that are now efficiently prevented and cured
[104]. Therefore, HCC has become the leading cause of
death in patients with cirrhosis.
Screening tests for HCC in patients with chronic viral 
hepatitis
Despite knowledge of the risk factors for HCC, screening
of HCC is controversial, as there have been no rand-
omized controlled studies demonstrating the efficacy of
screening for HCC. As HCC mostly occurs in patients with
cirrhosis, or at least advanced fibrosis, most studies have
been performed in these patients at risk. The most
frequently used tests have been serum alfa-fetoprotein
(AFP) and hepatic ultrasound (US).
There is one non randomized prospective cohort study
suggesting that HCC was detected earlier and was more
often resectable in patients who had twice yearly
screening with serum AFP and hepatic US than in patients
who had usual care [105].
Twenty-four studies, which included patients with
chronic hepatitis B or C or both, addressed the sensitivi-
ties and specificities of screening tests [106].
Serum AFP for detection of HCC was evaluated in 19 stud-
ies. They were relatively consistent in showing that the
sensitivity of serum AFP for detecting HCC increases from
very low levels to moderately high levels of 60 to 80% as
the threshold value decreased from 400 to 10 ng/mL, with
corresponding specificity decreasing from 100 to 70–
90%. A threshold between 10 and 19 ng/mL seems most
appropriate as sensitivity usually is moderately high (45
to 100%), with a specificity of 70 to 90%. It has been
shown that AFP is not always specific for HCC and titers
can increase with flares of active hepatitis [107].
Seven studies evaluated screening with US, reporting high
specificity of 95–100%, but variable sensitivity, varying
from 11–99% [94].
A surveillance study combining US and AFP in 1,125
patients with HCV, HBV or both, reported a sensitivity of
100% when using a serum AFP > 10 ng/mL together with
US, compared with a sensitivity of 75% using only AFP >
10 ng/mL and a sensitivity of 87% when using US alone
[108].
Computed tomography and magnetic resonance imaging
have a high sensitivity and specificity in detecting HCC,
but are too expensive to be used in surveillance [1].
The surveillance intervals studied varied from 3 to 12
months. In a study of patients with hepatitis B, the most
rapidly growing tumor increased from 1 to 3 cm in 5
months [109]. The ideal time for re-screening has notWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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been identified. Some investigators suggest a 4–5 month
interval, others have suggested that a 6-month interval
may be most appropriate [109,110]. It is suggested that in
case of concomitant HBV and HCV infection serum AFP
levels should be obtained every 3 months, and that per-
sistent AFP levels should prompt an aggressive imaging
search for HCC [61].
It can be concluded that screening patients with advanced
chronic hepatitis B or C with AFP and US may improve
detection of HCC, but further studies are needed whether
screening improves clinical outcomes.
Pathogenesis of hepatitis B and C-induced 
hepatocellular carcinoma
Introduction
Epidemiologic data indicate that chronic hepatitis B and
C are independent risk factors for development of HCC
[7,16]. Furthermore, animal models confirm the onco-
genic potential of HBV and HCV in the liver: transgenic
mice for hepatitis B and C [110,111], and natural models
such as the woodchuck infected with the woodchuck hep-
atitis virus, a hepadnavirus closely related to the HBV
[112].
Carcinogenesis is believed to be a multistage process,
occurring through a sequence of steps termed initiation,
promotion and progression. This process evolves over several
or many years. Tumor initiation begins in cells through
mutations induced by exposure to carcinogens. DNA
changes, maintained during successive cell divisions, acti-
vation of oncogenes and inactivation of suppressor genes
lead to dysregulation of the cell division and to immortal-
ization [113]. Tumor-initiated cells have a decreased
responsiveness to both intercellular and intracellular sig-
nals that maintain normal cellular architecture and regu-
late homeostatic growth. Tumor promotion  results in a
further selective clonal expansion of initiated cells. During
tumor progression, pre-malignant cells continue to develop
progressive phenotypic changes and genomic instability
(dysplasia), culminating as overt carcinoma [115].
More than 80% of HCC originate in cirrhotic livers.
Macronodules (macroregenerative nodules and adenom-
atous hyperplasia), irregular hepatocyte regeneration, and
some hyperplastic foci are considered as precancerous
[116-119]. Large cell dysplasia and small cell dysplasia are
considered to be risk factors for development of HCC
[120-122].
HBV and HCV can be implicated in the development of
HCC in an indirect way, through induction of inflamma-
tion, necrosis and chronic hepatocellular regeneration, or
directly by means of viral proteins or, in the case of HBV,
by creating insertional mutations by integration in the
genome of the hepatocyte.
Indirect carcinogenicity of HBV and HCV
In most patients with chronic hepatitis B and/or C the
occurrence of HCC is preceded by a process of longstand-
ing inflammation. It is probable that malignant transfor-
mation is related to continuous or recurring cycles of
hepatocyte necrosis and regeneration [123]. The resulting
accelerated cell turnover rate may act as a tumor promotor
by increasing the probability of spontaneous mutations or
damage to DNA by exogenous factors. The accelerated rate
of cell division leaves less time for altered DNA to be
repaired before the cell divides again, resulting in
transmission of altered DNA to the daughter cells. In this
way a series of mutations may accumulate in individual
cells over time. This process can lead to focal uncontrolled
liver cell growth and eventual malignant cell transforma-
tion [115,124]. Another mechanism of induction of
malignant transformation is the generation of mutagenic
reactive oxygen species as a result of the inflammatory
process, such as nitric oxide (NO), superoxide anion (O2
-
), hydroxyl radical (OH•) and hydrogen peroxide (H2O2)
[124].
Evidence for a causal role for chronic necro-inflammation
is provided by transgenic mice into which HBV preS/S
genes have been introduced. These mice overproduce pre
S1 protein that accumulates in the endoplasmatic reticu-
lum of hepatocytes, producing severe and prolonged
injury to these cells, initiating a response characterized by
inflammation, regenerative hyperplasia and transcrip-
tional deregulation that progresses ultimately to neopla-
sia [125].
Patterns of gene expression in cirrhosis and hepatocellular
carcinoma have recently been shown to be of value in pre-
dicting prognosis. Kim et al could identify, using the com-
plementary DNA microarray, a 273-gene signature that
distinguished high risk types of cirrhosis (hepatitis B, hep-
atitis C, hereditary hemochromatosis) from low risk types
(autoimmune hepatitis, PBC, alcoholic liver diseases)
[126]. The same 273-gene signature was present in sam-
ples from patients with proven HCC. A subset of 30 genes
was most significantly altered in both the high risk types
of cirrhosis and the HCC patients. The TACSTD1, a gene
associated with HCC development in other studies, is a
lead gene in this gene signature. Lee et al could identify a
limited number of genes that accurately predicted survival
in a series of 91 HCC patients [127]. The genes involved
are implicated in cell proliferation and apoptosis, but also
in ubiquitination and histone modification. Delpuech et
al identified distinct patterns of gene expression according
to the viral aetiology [128]. Finally, Hann et al could dem-
onstrate the presence of antibodies to differentiallyWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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expressed genes in hepatitis B and C, and this appeared to
be linked with decreased survival [129]. These discoveries
not only increase our insight in hepatocarcinogenesis, but
may ultimately lead to the development of clinically valu-
able preneoplastic and prognostic blood markers.
Direct carcinogenicity of HBV and HCV
Hepatitis B
A significant proportion of HBV-related HCCs arise in an
otherwise normal liver, implicating that the virus can also
be directly oncogenic [124].
It has been demonstrated that HBV integrates into the
DNA of the host cells. This integration may dysregulate
the control mechanisms on the cell cycle by chromosomal
abnormalities, production of viral proteins or alteration
of human genes and proto-oncogenes. It is, however, con-
troversial whether viral integration plays an important
role in the process leading to development of HCC. The
hepadnaviral integration process appears to involve
recombination mechanisms that do not preserve the viral
genome sequence. Thus it is impossible for the viral inte-
grant to function as a template for subsequent virus repli-
cation. Several studies suggest that DNA integration sites
are at random and that integration occurs at random
times during the course of a chronic viral infection
[130,131]. HBV integration can be present in chronically
infected liver tissue without evidence of HCC [132]. Non-
neoplastic hepatocytes may have a similar pattern of rear-
rangement of viral sequences following integration into
human DNA.
Chromosomal DNA instability
Several studies have shown that HBV DNA integration
enhances chromosomal instability. In many hepatic
tumors large inverted duplication insertions, transloca-
tions and micro- and macrochromosomal deletions have
been associated with HBV insertion [133-136]. These
changes can result in loss of important cellular genes,
sometimes involving tumor-suppressor genes and other
genes involved in the regulation of regeneration and
growth processes.
Trans-activation of cellular genes
HBV DNA may induce malignant transformation in
another way.
Mammalian hepadnaviruses contain a gene (the HBX
gene), of which the protein (HBX protein) can trans-acti-
vate several cellular promotors and upregulate their
expression of different cellular and viral genes [137,138].
Integrated HBX, even when truncated, frequently encodes
functionally active trans-activator proteins [139]. This pro-
tein has been shown to transform mouse fetal hepatocytes
into a full malignant phenotype [140]. There are studies
in transgenic mice with the HBX gene that developed
multifocal areas of altered hepatocytes, adenomas and
HCCs [110].
In contrast to mammalian hepadnaviruses associated
with HCC, avian hepadnaviruses such as the duck hepati-
tis virus or heron hepatitis virus, lack the HBX gene and
are not associated with HCC [123].
A gene that may be affected by the HBX gene is the p53
tumor suppression gene. This gene has been shown to
play an important role in hepatocarcinogenesis. It is
considered to negatively regulate the cell cycle. The HBX
protein has been shown to complex p53 protein and to
inhibit its function [141,142]. In a transgenic mouse
model it was shown that HCC development correlates
with p53 binding to HBX [143].
Oncogenes
It has been proposed that HBV acts as an insertion muta-
gen by integrating into the host genome and activating the
cellular proto-oncogenes c-myc, ras and c-fos [144].
The preS2/S gene is integrated in most HCCs associated
with HBV. When 3'-truncated it generates a truncated
protein that is oncogenic by trans-activating proto-onco-
genes c-myc and c-fos [145].
Growth factors
Growth factors and their receptors function as positive or
negative modulators of cell proliferation and differentia-
tion. Insulin-like growth factor-II and transforming
growth factor-β  expression correlate with HBX protein
expression in animal models [146,147], suggesting trans-
activation of these growth factors facilitating tumor
formation.
Role of PreS mutations
PreS deletion mutants accelerate the storage of large enve-
lope proteins in hepatocyte cytoplasm, which could
induce cytotoxic effects toward the development of end-
stage liver disease [148]. The accumulation of large enve-
lope protein can activate cellular promoters by inducing
endoplasmic reticulum stress [149]. Furthermore, pre-S1
sequences can stimulate the transcription of transforming
growth factor α  (TGFα ). Coexpression of TGFα  and
HBsAg could accelerate hepatocellular carcinogenesis by
stimulation of hepatocyte proliferation [150].
Allelic loss of chromosome 4q
Allelic loss of chromosome 4q is one of the most frequent
genetic aberrations found in HCC. It was found to be
associated with HBV-related hepatocarcinogenesis, proba-
bly by inactivation of a putative tumor suppressor gene
included in it [151].World Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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Hepatitis C
In contrast to HBV, HCV is an RNA virus that lacks a
reverse-transcriptase enzyme and cannot integrate into
the host genome. Thus, insertional mutagenesis can be
excluded as a pathogenic mechanism for the development
of HCC associated with chronic HCV infection. The
molecular pathogenetic mechanisms by which HCV con-
tributes to cell transformation remain unclear.
One possibility is that the development of HCC is simply
related to chronic necro-inflammatory liver disease. Over-
all, 97% of patients with HCV markers and HCC have cir-
rhosis [152,153], and most of the remainder develop
HCC in the presence of chronic hepatitis.
An alternative mechanism of HCV-induced hepatocar-
cinogenesis may be that HCV has a direct oncogenic
action. Viral replication might cause inappropriate expres-
sion of two growth factors that may be implicated in
hepatic carcinogenesis: transforming growth factor-α  and
insulin-like growth factor II [154,155].
The non-structural HCV protein NS3 has both protease
and helicase activity. HCV may therefore induce genomic
instability and favor mutations through its helicase activ-
ity [156]. The protein also has an activity similar to pro-
tein kinase A, and could disturb cellular homeostasis
[157].
The HCV envelope protein E2 and the non-structural pro-
tein  NS5A  inhibit RNA-dependent protein kinase, key
mediator of the antiviral, antiproliferative and anti-onco-
genic effect of interferon [158-160].
The HCV core protein has characteristics that imply that
this protein could function as a gene-regulator [161,162].
The presence of the protein in transgenic mice can induce
HCC [111]. After mutation, the HCV core protein can also
inhibit tumor suppressor genes such as p53, as has been
demonstrated in hepatic oncogenesis [163-165]. It has
recently been shown that the HCV core protein induces
nuclear factor κ B (NF-κ B), thereby suppressing TNF-α -
induced apoptosis [166]. This anti-apoptosis may be a
mechanism by which HCV leads to viral persistence and
possibly to hepatocarcinogenesis.
Prevention of hepatocellular carcinoma caused by viral 
hepatitis
Primary prevention
The most effective tool to prevent HCC is avoidance of the
risk factors such as viral infection by HBV or HCV. Any
action diminishing the potential transmission of contam-
inated blood products (uncontrolled blood transfusion,
needle sharing, invasive procedures without proper health
standards) will decrease the likelihood of viral spread.
The major advance has come from the availability of an
effective vaccine that protects against HBV.
In 1969, Taiwan was an hyperendemic area of HBV infec-
tion with a high rate of HBsAg positivity, 19% of the pop-
ulation being infected before the fourth decade of life. In
1976, HBsAg prevalence was > 80% in HCC in Taiwan
[167]. In 1984 a program to control cirrhosis and HCC
began. All neonates born to HBsAg positive mothers were
given hepatitis B vaccine in order to counter perinatal
infection. In 1986 all neonates were included in the
program. As a consequence, there was a decrease in HBsAg
positivity in six-year-olds from 10.6% in 1983–1984 to
0.8% in 1993–1994. There was a parallel decline in inci-
dence of childhood HCC (6–14 years old), in the cohort
born between 1980 and 1984. The incidence of liver can-
cer in children between 6 and 14 years old decreased to
zero for children born in 1986 and 1987 [168]. The
decline of HCC in children after universal vaccination can
be considered as an early indicator of the effectiveness of
vaccination in reducing the rate of HCC. Since the inci-
dence of HCC in Taiwan peaks in the sixth decade of life,
it may take 40 years or longer to see an overall decrease in
the rate of HCC as a result of the vaccination program.
Vaccination against HBV should become a health priority
together with the promotion of adequate health
standards.
Unfortunately, there is no vaccine against HCV. Up to
now, the only effective method to prevent its transmission
is the avoidance of contamination with infective blood
products.
Prevention of HCC in patients with previously 
acquired risk
Introduction
Chronic viral carriage is one of the main risk factors for the
development of HCC. Effective antiviral treatments have
been developed in recent years and this has changed the
management of viral infection.
Interferon-alfa is still considered the reference therapy for
HBeAg positive chronic hepatitis B. However, its efficacy
is limited, with seroconversion from anti-HBe negative to
anti-HBe positive in up to 40%. Only <10% of patients
become HBsAg negative [169]. Other possible treatments
are antiviral drugs such as lamivudine and adefovir
dipivoxil [12].
For the treatment of chronic hepatitis C, interferon-alfa
monotherapy yielded only limited response. Combina-
tion with ribavirin led to a significant increase in sus-
tained viral response to about 40% in treatment-naïve
patients [170,171]. Recently, the combination of
peginterferon-alfa and ribavirin improved the sustainedWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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viral response rate to nearly 60% in treatment-naïve
patients [172,173], and is now considered the reference
treatment.
It is under debate whether interferon-alfa-based treat-
ments are effective in declining the incidence of HCC in
chronic hepatitis B and C.
Anti-oncogenic effects of interferon-alfa
HCC prevention by interferon-alfa might be the result of
several direct or indirect mechanisms. Interferon has an
antiproliferative and pro-apoptotic effect [174]. Inter-
feron inhibits the expression of the c-myc oncogene and
induces the expression of anti-proliferative factors and
tumor suppressor genes [175-177]. In experimental ani-
mal models, the anti-neoplastic potential of interferon
was demonstrated in already established tumors. In a
transgenic mouse model it was demonstrated that early
and prolonged administration of interferon diminished
the severity of preneoplastic lesions and slowed down the
development of HCC [178]. Interferon-alfa also could
indirectly reduce the oncogenic risk by inhibition of syn-
thesis of viral proteins which potentially dysregulate the
cell cycle, and by enhancing the immune system eliminat-
ing not only infected hepatocytes but also initiated or
fully malignant cells. Furthermore, interferon-alfa has an
antifibrotic and anti-angiogenetic effect, which could also
have an influence on tumor development [179].
Interferon and antiviral treatment
Noncirrhotics
In patients with chronic hepatitis B, clearance of the
HBeAg after treatment with interferon-alfa is associated
with improved clinical outcome in terms of survival and
development of complications of cirrhosis [180]. Another
study confirmed these results and showed a reduction of
incidence of HCC in the responders [181]. As most of
these patients were non-cirrhotics at entry of the study, the
prophylactic effect of interferon on development of HCC
can be explained by prevention of cirrhosis development.
In Chinese patients with chronic hepatitis B infection,
however, interferon-alfa was of no long-term benefit in
inducing HBeAg conversion, or in the prevention of HCC
and other cirrhosis-related complications [182].
Cirrhotics
Seven studies investigated the possible effect of interferon
treatment on development of HCC in patients with
already established cirrhosis [183-189] (Table 4). A meta-
analysis was performed on these studies [190]. Interferon
seemingly decreased the rate of HCC in all trials, while a
significant difference was observed in 2 studies [183,186].
Virologic response was strongly associated with reduced
risk for HCC in the studies of Oon [183] and Mazzella
[184], suggesting that arrest of viral replication is a critical
factor. Subgroup analysis in relation to ethnic origin of
patients (European, Oriental) showed no preventive effect
of interferon on the development of HCC in the European
patients [190].
Table 4: Studies of treatment with interferon-α  for prevention of HCC in patients with hepatitis B-related cirrhosis
Author [reference] Country Type of 
study
Interferon 
regimen 
(duration in 
weeks)
Follow-up 
(range) in 
months
Sample 
size
Rate of HCC (n/n) Significance
Oon, 1992 [183] Singapore NRCT, P 10 MU daily, 10 
days/month (12)
12 (12–60) T 600
C 180
T: 0/600 (0%)
C: 10/180 (5.6%)
Significant
Mazzella, 1996 [184] Italy NRCT, P 10 MU tiw (26) 49 (12–119) T 34
C 28
T: 2/34 (5.9%)
C: 4/28 (14.3%)
Not significant
Fattovich, 1997 [185] Europe NRCT, P ≥  300 MU (12–52) 84 (80–92) T 40
C 50
T: 3/40 (7.5%)
C: 4/50 (8.0%)
Not significant
Ikeda, 1998 [186] Japan NRCT, P 12 MU/wk (26) 84 (6–168) T 94
C 219
T: 10/94 (10.6%)
C: 51/219 (23.3%)
Significant
IHCSG, 1998 [187] Argentina, 
Germany, Italy, 
Saudi Arabia
NRCT, P 9–30 MU/wk for 
3–30 months
(36–250) T 49
C 97
T: 8/49 (16.3%) C: 
18/97 (18.6%)
Not significant
Benvegnù, 1998 [188] Italy NRCT, P 6–10 MU (20–26) 72 T 10
C 18
T: 0/10 (0%)
C: 4/18 (22.2%)
Not significant
Di Marco, 1999 [189] Italy NRCT, P 655 MU 93 (6–180) T 26
C 60
T: 2/26 (7.7%)
C: 6/60 (10%)
NR
NRCT: non-randomized controlled trial
P: prospective
T: treated
C: controls
MU: million units
NR: not reportedWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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It should be noted that the studies are very heterogeneous
and that none of them were randomized controlled trials,
so that the results should be interpreted with caution.
A recent study showed a significant reduction of the risk
of HCC in patients with chronic hepatitis B and advanced
fibrosis or cirrhosis, treated with lamivudine for a maxi-
mum of five years, compared to placebo [191].
Interferon treatment in HCV patients and HCC prevention
Noncirrhotics
Three studies assessed whether interferon treatment pre-
vents the development of HCC in noncirrhotic patients
with chronic hepatitis C [192-194] comprising 3,798
noncirrhotic patients treated with interferon-alfa mono-
therapy. Pooled together, the incidence of HCC was 60/
2,532 (2.37%) in sustained virological responders and
76/1,266 (5.29%) in nonresponders. In a study of 291
noncirrhotic patients with chronic hepatitis C who were
nonresponders to interferon therapy and followed for 6–
117 months after therapy, the incidence of HCC was sig-
nificantly lower in patients who received > 500 MU of
interferon. Patients with a transient response (i.e. relapse
after end of treatment) had a significant lower rate of HCC
development (4/166 = 2.4%) than nonresponders (12/
125 = 9.6%) [195].
This anti-oncogenic benefit can presumably be explained
by an arrest or slowing down of the cirrhogenic process.
Cirrhotics
The findings of 13 studies of interferon treatment and
development of HCC in HCV-infected patients with com-
pensated cirrhosis are summarized in Table 5[45,184-
186,194,196-204]. Only 3 studies were randomized
[199,201,202,204], the remainders were observational
cohort studies. Statistical combination of data is not pos-
sible because of different definitions of response (bio-
chemical, virological), different dose schedules for
interferon and different duration of follow-up. All studies
showed a lower risk for development of HCC in the inter-
feron-treated patients, suggesting that interferon may pre-
vent HCC in compensated cirrhosis caused by hepatitis C.
The overall result was largely influenced by three Japanese
studies [194,198,201,202], which had the highest inci-
dence of HCC in untreated patients (5–6% per year). This
may be explained by intensiveness of the screening pro-
grams, but also by genetic, environmental or viral factors.
Four European studies failed to document a significant
reduction in risk of developing HCC [45,196,199]. In the
studies of Fattovich et al [196] and Bruno et al [45],
interferon-alfa treatment showed a decrease in incidence
of HCC in univariate analysis. However, this was not
present in multivariate analysis. In the study of Fattovich
[196], a very low natural incidence of HCC was observed,
rendering difficult to show a significant decrease. The pro-
spective randomized controlled trial of Valla et al [199]
also failed to show a significant effect of interferon treat-
ment on the development of HCC. However, the number
of patients in this study was limited and the follow-up rel-
atively short. Also a recently published randomized con-
trolled study from Italy comprising 51 interferon-treated
and 71 untreated patients with compensated hepatitis C-
cirrhosis, failed to demonstrate any reduced risk in devel-
opment of HCC after a mean follow-up of 96.5 months
[204].
In most studies, virological and/or biochemical response
are associated with a lower risk of development of HCC,
which is less clear in nonresponders. In the study of Imai
et al. [198], patients with sustained biochemical response
after interferon therapy were at low risk for development
of HCC (risk ratio versus controls 0.06; 0.95 in nonre-
sponders). Also in the study of Mazzella [184], a statisti-
cally significant effect of interferon treatment was
demonstrated when biochemical responders were com-
pared with controls but not when compared with nonre-
sponders. In the study of Benvegnù et al [188], the
beneficial effect of interferon treatment on development
of HCC was independent of the type of response. In the
study of Yoshida et al [194] the risk for HCC was reduced
especially among patients with sustained virological but
also merely biochemical response that tested positive for
HCV RNA. Okanoue et al [200] studied 1,148 patients
with chronic hepatitis C treated with interferon-alfa, 40 of
them having cirrhosis (fibrosis stage F4). They were fol-
lowed for 1–7 years after therapy. The cumulative inci-
dence of HCC was significantly decreased in sustained
biochemical responders, compared to nonresponders and
transient responders, in patients with stage F2 fibrosis, but
not in the more advanced stages F3 and F4. In the study of
Testino et al [204] HCC did also develop in sustained bio-
chemical responders. Tanaka et al [205], however, demon-
strated in 55 patients with HCV-cirrhosis that long-term
administration of interferon prevented HCC in those with
biochemical and virological response, whereas HCC only
appeared in nonresponders.
The mechanisms by which an interferon treatment might
reduce the risk of HCC development in cirrhosis caused
by HCV independent of virological response remains
speculative. Maintenance of serum transaminases at low
levels may protect against the development of HCC as
hepatocyte necrosis, cell damage and increase in hepato-
cyte replication result in increased DNA damage, influenc-
ing hepatocarcinogenesis. Other possible mechanisms for
prevention of HCC are the direct and indirect effects of
interferon. It is, however, perplexing that only 6 or 12
months of therapy can produce this benefit without viro-
logical response. Because of potential biases in the pub-World Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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lished trials it is premature to advocate the use of
interferon as established therapy in HCV infected patients
with cirrhosis to prevent HCC. Prospective randomized
controlled trials should reproduce the findings in large
numbers of patients before a definitive conclusion on the
long term effects of interferon in HCV cirrhosis can be
established.
It must also be realized that a sustained virological
response to interferon-alfa monotherapy can be obtained
only in 0–8% of patients with cirrhosis [206-208]. New
treatments are now available for chronic hepatitis C,
which are more performant in difficultly to treat cases as
patients with cirrhosis. The combination of interferon-
alfa and ribavirin results in a sustained virologic response
in up to 25% of cirrhotics due to hepatitis C [207]. A sus-
tained virologic response of 32% was reported after
peginterferon-alfa-2a monotherapy [207] and of 43%
after combination of peginterferon-alfa2a and ribavirin
[173]. It should be investigated in prospective trials, tak-
ing into account the sustained virological and biochemi-
cal responses if these more performant treatment
regimens will also influence favorably the incidence of
HCC, as no data on the long-term effects of these treat-
ments are available up to now.
Secondary prevention
A few sudies focus on the possible role of intereron in the
secondary prevention of HCC recurrence in patients with
chronic hepatitis B and C after curative resection or
ablation.
Ikeda et al [209] showed that interferon prevented HCC
recurrence after complete resection or ablation of the pri-
Table 5: Studies on treatment with interferon-α  for prevention of HCC in patients with HCV-related cirrhosis
Author [reference] Country Type of study Interferon 
regimen 
(duration in 
weeks)
Follow-up 
(range) in 
months
Sample 
size
Rate of HCC 
(n/n)
Significance
Mazzella, 1996 [184] Italy NRCT, P 3 MU tiw (52) 32 (12–71) T 193
C 91
T: 5/193 (2.6%)
C: 9/91 (9.9%)
Significant
Fattovich, 1997 [196] Europe NRCT, P ≥  200 MU 60 (1–153) T 193
C 136
T: 7/193 (3.6%)
C: 16/136 (11.8%)
Not significant
Bruno, 1997 [45] Italy NRCT, P 6 MU tiw (26) 68 (60–84) T 82
C 81
T: 6/82 (7.3%)
C: 14/81 (17.3%)
Not significant
Serfaty, 1998 [197] France NRCT, P 3 MU tiw (48) 40 (6–72) T 59
C 44
T: 2/59 (3.4%)
C: 9/44 (20.1%)
Significant
IHCSG, 1998 [187] Argentina, 
Germany, Italy, 
Saudi Arabia
NRCT, R 9–30 MU/wk 
(3–30 months)
(36–250) T 232
C 259
T: 2/232 (0.9%)
C: 48/259 (18.5%)
Significant
Imai, 1998 [198] Japan NRCT, R 480 MU (26) 48 (3–65) T 32
C 20
T: 8/32 (25%)
C: 7/20 (35%)
Significant
Benvegnù, 1998 [188] Italy NRCT, P 3–6 MU tiw 
(26–52)
72 T 75
C 77
T: 4/75 (5.3%)
C: 20/77 (26.0%)
Significant
Valla, 1999 [199] France RCT 3 MU TIW (48) 40 (37–53) T 47
C 52
T: 5/47 (10.6%)
C: 9/52 (17.3%)
Not significant
Yoshida, 1999 [194] Japan NRCT, R 480 MU (23) 52 T 230
C 107
T: 33/230 (14.3%)
C: 29/107 (27.1%)
NR
Okanoue, 1999 [200] Japan NRCT, R 3–10 MU qd 
or tiw (16–24)
1–7 years T 40
C 55
T: 7/40 (17.5%)
C: 22/55 (40.0%)
NR
Nishiguchi, 1995/2001 
[201,202]
Japan RCT 6 MU tiw 
(12–24)
104 (31–110) T 45
C 45
T: 12/45 (26.7%)
C: 33/45 (73.3%)
Significant
Gramenzi, 2001 [203] Italy RCT, P 741 MU 72 T 72
C 72
T: 6/72 (8.3%)
C: 19/72 (26.4%)
Significant
Testino, 2002 [204] Italy RCT 3 MU tiw (52) 96.5 ± 18 T 51
C 71
T: 15.51 (29.4%)
C: 24/71 (33.8%)
Not significant
NRCT: non-randomized controlled trial
RCT: randomized controlled trial
P: prospective
R: retrospective
NR: not reported
T: treated
C: controls
MU: million unitsWorld Journal of Surgical Oncology 2005, 3:27 http://www.wjso.com/content/3/1/27
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mary tumor depending on the clearance of HCV viremia.
Kubo et al [210] reported a decreased recurrence after sur-
gical resection independent of clearance of HCV or nor-
malization of serum ALT. Another study demonstrated
prevention of HCC recurrence after medical ablation ther-
apy for primary tumors in hepatitis B but not in hepatitis
C patients by the use of interferon-alfa [211].
Conclusions
Chronic hepatitis B and C, mostly in the cirrhotic stage,
are responsible for the majority of the hepatocellular car-
cinomas worldwide. The rising incidence in HCC in devel-
oped countries during the last two decades is due to the
increasing rate of hepatitis C infection and improvement
of the clinical management of cirrhosis.  Vaccination
against hepatitis B seems to protect against the develop-
ment of HCC.
In patients with chronic hepatitis B or C, interferon alpha
treatment in a noncirrhotic stage is protective for HCC
development in responders, probably by prevention of
cirrhosis development. When cirrhosis is already present,
the protective affect is less clear. Further prospective long-
term studies should be performed on the new treatments
for chronic hepatitis B and C. Some studies also suggested
a favourable effect of interferon alpha in the prevention of
HCC recurrence in patients with chronic hepatitis B and C
after curative resection or ablation.
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